IASO to Start China Trial of Injected CAR-T Therapy for Autoimmune Disease

Shanghai IASO Bio reported China’s NMPA approved its IND for an injected BCMA CAR-T therapy for patients with Neuromyelitis Optica Spectrum Disorder (NMOSD), an autoimmune disease caused by demyelination of the central nervous system. The IND application was based on clinical data from an investigator-initiated clinical study. Equecabtagene Autoleucel was safe and improved symptoms in all 12 patients.  Neuromyelitis optica, which primarily affects the eye nerves (optic neuritis) and the spinal cord (myelitis), is characterized by outbreaks that can cause permanent damage. IASO develops cellular therapeutics and antibody drugs. More details....

Share this with colleagues: